Ph1 Lobeline Interaction Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if there are significant cardiovascular or other interactions between sublingual lobeline and intravenous methamphetamine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

NCT00519259

Methamphetamine Dependence

UNKNOWN PHASE1

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074

Amphetamine-Related Disorders

UNKNOWN PHASE1

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

NCT01603147

Methamphetamine Abuse

COMPLETED PHASE1

Interactions Between Intravenous (IV) Cocaine and Lofexidine

NCT01148992

Cocaine Related Disorders

TERMINATED PHASE1

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657

Amphetamine-Related Disorders

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methamphetamine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lobeline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be between the ages of 18 and 45 years of age
* Be in general good health with a history of methamphetamine (MA) abuse (but not dependence)
* If female and of child bearing potential, agrees to use birth control
* Be able to understand and provide written informed consent
* Have a body mass index between 18 and 30
* Have reported use of (MA) during the past three months without experiencing adverse consequence plus a life time MA or amphetamine use history of at least four occasions of use
* Have a negative drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening and at the time of admission